Gregg Sherman, MD
National Association for Continuing Education
Harvey C. Parker, Ph.D., CCMEP
National Association for Continuing Education
Joshua Kilbridge, President
San Francisco, CA
While once thought of as a childhood disorder that primarily affected “disruptive” boys, ADHD is now known to persist into adulthood in approximately 60% of cases with an overall prevalence of 3-4% of US adults. Unlike earlier beliefs, it is now known that the nearly as many women have ADHD in adulthood with a male-female prevalence of 1.6: to 1. The condition can be detrimental to many areas of life including work, daily activities, social and family relationships and psychological and physical well-being.
Appropriate treatment of ADHD in adults can provide dramatic symptomatic improvement with some of the largest treatment effects of any medical condition.
Recognition and treatment of adult ADHD is important, especially because of the potential for dramatic symptomatic improvement. However, the condition is underdiagnosed and undertreated in practice.
This activity utilizes a flipped classroom design. This begins with a foundational self-study followed by an online live webinar, which will be available on-demand after the live event, where all participants will have the opportunity to interact with the faculty and other learners. This provides an opportunity to discuss more specific management questions and strategies of care.
DISCLOSURE POLICY STATEMENT:
It is the policy of NACE to ensure balance, independence, objectivity, and scientific rigor in all of its educational activities. NACE assesses conflict of interest with its faculty, planners and managers of CME activities. Conflicts of interest that are identified are resolved by reviewing that presenter's content for fair balance and absence of bias, scientific objectivity of studies utilized in this activity, and patient care recommendations.
While NACE endeavors to review faculty content, it remains the obligation of each physician or other healthcare practitioner to determine the applicability or relevance of the information provided from this course in his or her own practice.
DISCLOSURE OF CONFLICTS OF INTEREST:
Gregg Mattingly, MD serves as a Speaker for Allergan, Lundbeck, Merck, Otsuka, Shire, Sunovion, Takeda and Vanda. Dr. Mattingly also serves as a consultant for Alkermes, Allergan, Forum, Lundbeck, Merck, Otsuka, Perdue, Rhodes, Shire, Sunovion, Takeda and Vanda. Additionally, he serves as a researcher for Akili, Alcobra, Alkermes, Allergan, Boehringer, Forum, Janssen, Medgenics, NLS-1 Pharma AG, Reckitt Benckiser, Shire, Sunovion, Supernus and Takeda.
Gregg Sherman, MD has no real or apparent conflicts of interest to report.
Harvey Parker, PhD has no real or apparent conflicts of interest to report.
Joshua Kilbridge has no real or apparent conflicts of interest to report.
DISCLOSURE OF UNLABELED USE:
NACE requires that faculty participating in any CME activity disclose to the audience when discussing any unlabeled or investigational use of any commercial product or device not yet approved for use in the United States.
The opinions expressed during the educational activity are those of the faculty and do not necessarily represent the views of NACE. The information is presented for the purpose of advancing the attendees' professional development.
The National Association for Continuing Education is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.
The National Association for Continuing Education is also approved as a provider of nurse practitioner continuing education by the American Association of Nurse Practitioners. AANP Provider Number 121222.
This CME activity was planned and produced in accordance with the ACCME Essentials and the AANP CE Standards and Policies and AANP Commercial Support Standards.
CREDIT DESIGNATION STATEMENT:
The National Association for Continuing Education designates this enduring activity for a maximum of 1.0 AMA PRA Category 1 Credit™. Physicians should claim credit commensurate with the extent of their participation in the activity.
The National Association for Continuing Education is approved as a provider of nurse practitioner continuing education by the American Association of Nurse Practitioners. AANP Provider Number 121222. This program has been approved for 1.0 contact hour of continuing education (which includes 0.25 hours of pharmacology).
TO OBTAIN CME CREDITS:
- Read the learning objectives and front matter.
- Participate in the activity.
- Complete the post-test and activity evaluation.
- You must score 60% or higher on the post-test to receive credit for this activity.
- Physicians who successfully complete the post-test and evaluation will receive AMA PRA Category 1 credit.
- Nurse Practitioners who successfully complete the post-test and evaluation will receive AANP CE credit. All other participants who successfully complete the post-test and evaluation will receive a certificate of participation.
- All other participants who successfully complete the post-test and evaluation will receive a certificate of participation.
COURSE FORMAT/MEDIUM: Internet CME Activity
ESTIMATED TIME TO COMPLETE: 60 minutes
This activity is provided by The National Association for Continuing Education.
Supported by an educational grant from Shire.